Fig. 1: Illustration in diagram form depicting the process of preparing nAg-MRDE/Mn + CXCL10@Gel and antitumor immune responses. | Nature Communications

Fig. 1: Illustration in diagram form depicting the process of preparing nAg-MRDE/Mn + CXCL10@Gel and antitumor immune responses.

From: Neoantigens combined with in situ cancer vaccination induce personalized immunity and reshape the tumor microenvironment

Fig. 1

a The steps involved in the preparation of nAg-MRDE/Mn and nAg-MRDE/Mn+CXCL10@Gel. b Schematic diagram of personalized immunotherapy by combining neoantigens with in situ cancer vaccine and converting the tumor from cold to hot. BMDCs, mouse bone marrow-derived DCs; DEs, dendritic cell-derived exosomes; Rh2, ginsenoside Rh2; Mel, melittin; OVA, ovalbumin; PVA, polyvinyl alcohol; BSA, bovine serum albumin; dsDNA, double-stranded DNA; cGAS, cyclic GMP-AMP synthase; cGAMP, cyclic GMP-AMP; STING, stimulator of interferon genes; TBK1, TANK binding kinase 1; IRF3, interferon regulatory factor 3; CTL, cytotoxic T lymphocyte; GLUT1, glucose transporter type 1; SR-BI, scavenger receptor class B type I; ROS, reactive oxygen species.

Back to article page